C07K 2317/66
Comprising a swap of domains
Official title: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
C07K2317/66 (Comprising a swap of domains) appears on 139 US grants and 339 published applications in this corpus.
Search patents in C07K- Granted patents
- 139
- Published applications
- 339
- Assignees
- 106
- Inventors
- 577
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 4 |
| 2011 | 0 | 1 |
| 2012 | 0 | 3 |
| 2013 | 0 | 10 |
| 2014 | 2 | 12 |
| 2015 | 5 | 10 |
| 2016 | 3 | 14 |
| 2017 | 3 | 25 |
| 2018 | 11 | 26 |
| 2019 | 10 | 30 |
| 2020 | 18 | 36 |
| 2021 | 16 | 35 |
| 2022 | 12 | 33 |
| 2023 | 17 | 30 |
| 2024 | 17 | 24 |
| 2025 | 13 | 23 |
| 2026 | 12 | 23 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and antibody compositions for tumor treatment29 Sep 2026US 12,747,300 B2Regeneron Pharmaceuticals, Inc.
- Multi-specific antibodies and methods of making and using thereof15 Sep 2026US 12,735,487 B2Systimmune, Inc.
- Antibodies binding to GPRC5D25 Aug 2026US 12,715,923 B2Hoffmann-La Roche Inc.
- Monoclonal antibodies against BCMA26 May 2026US 12,637,522 B2Bristol-Myers Squibb Company
- Bispecific caninized antibodies for treating atopic dermatitis19 May 2026US 12,630,640 B2Intervet Inc.
- Antibodies for use in canines1 Oct 2026US 2026/0297171 A1Invetx, Inc.
- Bispecific t cell activating antigen binding molecules10 Sep 2026US 2026/0265377 A1Hoffmann-La Roche Inc.
- Antibody combination specifically binding to trail or fasl, and bispecific antibody20 Aug 2026US 2026/0242494 A1Beijing Solobio Genetechnology Company Ltd.
- Polypeptide modification method for purifying polypeptide multimers30 Jul 2026US 2026/0217760 A1Chugai Seiyaku Kabushiki Kaisha
- Igg fc variants with reduced self-association30 Jul 2026US 2026/0217865 A1The Regents of the University of Michigan
Most cited
By later US patents
- Tri- or tetraspecific antibodies59US 8,796,424 B2Hoffmann-La Roche Inc. · 2014
- Bispecific, tetravalent antigen binding proteins42US 8,703,132 B2Hoffmann-La Roche Inc. · 2014
- Engineered opsonin for pathogen detection and treatment39US 9,150,631 B2President and Fellows of Harvard College · 2015
- Heterodimeric antibodies that bind CD3 and PSMA34US 10,227,410 B2Xencor, Inc. · 2019
- Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies30US 8,945,552 B2Hoffmann-La Roche Inc. · 2015